Clinical Trial News Archive
Get news By email or subscribe to our News feeds.
August 2009
August 3
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
ImmunoGen Announces Encouraging New Clinical Data with the Company's IMGN901 Compound in the Treatment of Small-Cell Lung Cancer
SuperGen's MP-470 Demonstrates Clinical Benefit in Small Cell Lung Cancer and Neuroendocrine Tumor Patients
Results from a Phase 2 Study of ABRAXANE In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
August 4
Int'l Swine Flu Conference Add More Breakout Sessions
Technology Vision Group Presents BioPartnering Europe's Extensive and Topical Conference Program
TAXI "Driver" Lavoie Headed to the CTAM Summit
Advaxis Executive VP of Science and Operations Dr. John Rothman to Present at the 2009 Immunotherapeutics & Vaccine Summit (IMVACS)
VivaGel Demonstrates Anti-HIV and Herpes Activity Following Human Administration
Merck KGaA Presented New Data On the Combination of Erbitux with Standard First-Line Therapy in Patients with NSCLC
Novel Chemotherapy Agent Bendamustine Significantly More Effective First-Line Therapy than Chlorambucil in CLL
August 5
First Human Demonstration of Significant, Persistent Antibody Response Using Electroporation-Delivered DNA Vaccine Published in Human Gene Therapy
Phase Forward to Present at the 11th Annual Pacific Crest Technology Leadership Forum
Results From TH-302 Clinical Trials Presented at International Lung Cancer Meeting
Clinical Data Evaluating Amrubicin as Potential Therapy for Patients with Small Cell Lung Cancer Presented at 13th World Conference on Lung Cancer
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
RXi Pharmaceuticals Presented Data from Animal Trials Demonstrating the Utility of Self-Delivering RNAi at IBC's Oligonucleotide Therapeutics Conference
GeoVax Labs, Inc. Provides Clinical Studies Update
M. D. Anderson Study Finds Common Diabetic Therapy Reduces Risk of Pancreatic Cancer
Heartbeat's Bill Drummy Will Be Featured at HBA -- The Beauty Event in New York City
The Group Room to Broadcast Live from the 13th World Conference on Lung Cancer
Data Demonstrate New Imiquimod Formulation as Short Course Treatment for Actinic Keratosis
MIXX 2009 To Showcase Powerful Roster of the Best Minds Fueling Interactive's Creative Revolution
FDA Accepts NDA for New Imiquimod Product
August 6
Scientific Article Outlines Role of Galectin-3 in Heart Failure Development and Progression
Med Ad News? PharmaMed Marketing & Media Conference Announces Updates to the Three Innovative Sales-Force-Effectiveness, Digital Marketing & Patient Centered Communication Tracks
Galapagos NV (BE) - Galapagos successfully completes first Phase I study for GLPG0259
Opaxio Combined with Alimta Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia
Alzheimer's Disease is the Focus of TBSI Annual Neuroscience Symposium
August 7
August 10
NanoViricides, Inc. Anti-Herpes Drug Candidate Reduces Viral Load by 99.99%
Human Swine Flu Conference to be Held in Washington DC Next Week
Positive Top Line Results from Phase III Study (MARVEL) of anti-influenza Virus Agent 'CS-8958'
Depomed Reports Encouraging Results of its Phase I Trial for DM-1992 Program in Parkinson's Disease
Vectibix in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
August 11
Knopp Neurosciences to Present Phase 2 Results of KNS-760704 in ALS
AVANIR Announces Positive Phase III Study Results for Zenvia
Array BioPharma Reports Positive Results of Its Oral Glucokinase Activator in Type 2 Diabetes Patients
Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
Javelin Pharmaceuticals Reports Ereska (Intranasal Ketamine) Phase III Trial Results in Postoperative Orthopedic Pain
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
AVANIR Pharmaceuticals Schedules Conference Call to Discuss Phase III Results for Zenvia in Pseudobulbar Affect
As Aging Populations Rise, World-Renowned Aging Experts Will Convene to Share Insights into How to Achieve a Healthy Lifespan
Pluristem Therapeutics Will Present the Phase I Study for PLX-PAD in Critical Limb Ischemia at MSC2009 Regenerative Medicine and Adult Stem Cell Therapy Conference
Endocyte Announces Positive Results from a Phase II Clinical Study of EC145 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Romaco at PackExpo in Las Vegas
August 12
NanoViricides, Inc. Herpes Study Results Discussed on CBS News Report
Endocyte announces positive results from a Phase II clinical study of EC145 in patients with advanced non-small cell lung cancer (NSCLC)
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse® (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona ) in Mild to Moderate Alzheimer's Disease
CytRx's Drug Candidate INNO-206 Produces Statistically Significant Tumor Shrinkage in Animal Model of Small Cell Lung Cancer
Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
NuPathe Reports Positive Phase III Results for Zelrix, a Novel Transdermal Patch for Acute Migraine
August 13
August 14
Tranzyme Pharma to Present at American Chemical Society (ACS) 2009 National Meeting
Risk of suicidal behaviour with antidepressants strongly linked to age
No clear evidence that antivirals prevent complications in children with seasonal flu
BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Program
Kuros Announces Encouraging Phase IIa Data with KUR-212 in Patients with Burns Requiring Mesh Grafting
Genmab Announces Preliminary Top-Line Results for Arzerra in Front Line CLL
Metabolomics Aids in Understanding Mechanisms of Commonly Used Drugs
Cannabis Science Reports On Two Cannabis-Based Drug Release Programs
August 17
August 18
BioSante Pharmaceuticals Reports 100% Protection From H1N1 Challenge When Using BioVant Adjuvanted Vaccine
NanoBio to Present Preclinical Data on its Novel, Nanoemulsion-based Vaccine Adjuvant Platform at the Immunotherapeutics & Vaccine Summit
Vectibix Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
GlaxoSmithKline and Genmab Announce Results from a Study of Arzerra in Rituximab Refractory Follicular NHL
Sinovac Reports Top-Line Preliminary Results of H1N1 Vaccine Clinical Trials
New Study Reinforces Safety Profile of Gardasil, the Cervical Cancer Vaccine
August 19
Forest Announces Phase IIb Study Results For Oglemilast in Chronic Obstructive Pulmonary Disease
PCI Biotech Holding (NO) - Anti-tumour drug more potent with light-directed delivery
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease
Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
Novavax Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
Lilly Reports on Outcome of Phase III Study of Arzoxifene
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease
Study Examines Adverse Events Associated With Human Papillomavirus Vaccine
Ablynx Announces Positive Phase I Results for Subcutaneous Administration of it's Ant-thrombotic NanobodyR (ALX-0681)
August 20
Study published in the NEJM shows that oral Iressa (gefitinib) Provides Superior Efficacy Compared To Doublet Chemotherapy In Phase III First-Line Study In Non Small Cell Lung Cancer
Results In The New England Journal Of Medicine Confirm Novartis Drug Femara Is Superior to Tamoxifen After Breast Cancer Surgery
Study shows pain is "intolerable" for over a third of cancer patients, but nearly three quarters are battling the burden of side effects as a result of their pain treatment
PCF Funding for Bone Metastasis Research Supports New Drug to Improve Lives of Prostate Cancer Patients
Anti-Tumour Drug More Potent With Light-Directed Delivery
August 25
CytRx's Arimoclomol Demonstrates Statistically Significant Cellular Evidence of Both Neuroprotection and Neuroregeneration in Animal Stroke Study
Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
NexBio Demonstrates DAS181 (Fludase*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
Resverlogix Phase 1b/2a Study Meets Primary Endpoint
August 26
BioAlliance Pharma Announces Positive Preliminary Pivotal Phase III Results in Herpes Labialis with Acyclovir Lauriad
Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress
ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
Hormone Therapy for Prostate Cancer Patients With Certain Heart Conditions Associated With Increased Risk of Death
Genetic Variation Associated With Poorer Response, Cardiovascular Outcomes With Use of Clopidogrel
Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products
NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting
MoxDuo IR Demonstrates Fewer Side Effects Than Percocet
Genmab Announces Positive Top-Line Results for Arzerra in Front Line NHL
Nymox's NX-1207 Shows Major Effect on Liver Cancer
New Data Published in the Journal Population Health Management Show Significant Misuse of Pain Medication Among Chronic Pain Population
August 27
Medgenics, Inc. Announces Patient Nearing Unprecedented 11 Months of Anemia Relief in Clinical Trial From Single Treatment of Biopump Tissue Technology; News Follows Significant Interest of Strategic Partner for New Application
UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus
Eileen May Named Senior Vice President of Operations at Scientific Voice
August 28
Four Studies Published in The Lancet Show Roflumilast (Daxas), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations
Forest Laboratories, Inc. and Nycomed Announce a Conference Call to Review Publication of Daxas Phase III Clinical Trial Results
Blood Thinner Causes Stroke in Some Dialysis Patients
Nycomed/Forest - Ph III Data Published in The Lancet Showing that Roflumilast (Daxas), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations
Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
BioAlliance Pharma to present at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine (Bergen, Norway, August 31 to September 2, 2009)
